Use of therapeutic drug monitoring in pharmacoeconomics

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The use of therapeutic drug monitoring (TDM) for drugs with a narrow therapeutic range has contributed substantially to the literature. The pharmacoeconomics of this service for hospitalized patients has demonstrated significant hospital savings. Appropriate use of this pharmacy-based service has demonstrated savings, reduction in total length of hospitalization, and cost avoidance with aminoglycoside-induced nephrotoxicity. Use of a Clinical Pharmacokinetic Service (CPS) for inpatient theophylline therapy and outpatient anticonvulsant therapy documents the pharmacoeconomic benefits provided by this service to both in- and outpatients. This report will discuss current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM.

Original languageEnglish
Pages (from-to)608-610
Number of pages3
JournalTherapeutic Drug Monitoring
Volume15
Issue number6
StatePublished - 1993

Fingerprint

Pharmaceutical Economics
Drug Monitoring
Monitoring
Inpatients
Outpatients
Pharmaceutical Preparations
Pharmaceutical Services
Cost benefit analysis
Pharmacokinetics
Aminoglycosides
Theophylline
Anticonvulsants
Cost-Benefit Analysis
Hospitalization
Therapeutics
Costs and Cost Analysis
Costs

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health
  • Toxicology

Cite this

Use of therapeutic drug monitoring in pharmacoeconomics. / Destache, Christopher J.

In: Therapeutic Drug Monitoring, Vol. 15, No. 6, 1993, p. 608-610.

Research output: Contribution to journalArticle

@article{dbb5659be5ce43799a840629b83aa006,
title = "Use of therapeutic drug monitoring in pharmacoeconomics",
abstract = "The use of therapeutic drug monitoring (TDM) for drugs with a narrow therapeutic range has contributed substantially to the literature. The pharmacoeconomics of this service for hospitalized patients has demonstrated significant hospital savings. Appropriate use of this pharmacy-based service has demonstrated savings, reduction in total length of hospitalization, and cost avoidance with aminoglycoside-induced nephrotoxicity. Use of a Clinical Pharmacokinetic Service (CPS) for inpatient theophylline therapy and outpatient anticonvulsant therapy documents the pharmacoeconomic benefits provided by this service to both in- and outpatients. This report will discuss current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM.",
author = "Destache, {Christopher J.}",
year = "1993",
language = "English",
volume = "15",
pages = "608--610",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Use of therapeutic drug monitoring in pharmacoeconomics

AU - Destache, Christopher J.

PY - 1993

Y1 - 1993

N2 - The use of therapeutic drug monitoring (TDM) for drugs with a narrow therapeutic range has contributed substantially to the literature. The pharmacoeconomics of this service for hospitalized patients has demonstrated significant hospital savings. Appropriate use of this pharmacy-based service has demonstrated savings, reduction in total length of hospitalization, and cost avoidance with aminoglycoside-induced nephrotoxicity. Use of a Clinical Pharmacokinetic Service (CPS) for inpatient theophylline therapy and outpatient anticonvulsant therapy documents the pharmacoeconomic benefits provided by this service to both in- and outpatients. This report will discuss current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM.

AB - The use of therapeutic drug monitoring (TDM) for drugs with a narrow therapeutic range has contributed substantially to the literature. The pharmacoeconomics of this service for hospitalized patients has demonstrated significant hospital savings. Appropriate use of this pharmacy-based service has demonstrated savings, reduction in total length of hospitalization, and cost avoidance with aminoglycoside-induced nephrotoxicity. Use of a Clinical Pharmacokinetic Service (CPS) for inpatient theophylline therapy and outpatient anticonvulsant therapy documents the pharmacoeconomic benefits provided by this service to both in- and outpatients. This report will discuss current literature with regard to pharmacoeconomics and cost-benefit analysis of TDM.

UR - http://www.scopus.com/inward/record.url?scp=0027438073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027438073&partnerID=8YFLogxK

M3 - Article

C2 - 8122303

AN - SCOPUS:0027438073

VL - 15

SP - 608

EP - 610

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -